Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MOVE | Movano | $16.74 | $9.77 | 140.17% | 42.4M | $6.3M | $4.67$55.00 |
| BNAI | Brand Engagement Network | $16.48 | $7.82 | 90.30% | 36.3M | $39M | $1.18$18.30 |
| DRCT | Direct Digital | $4.11 | $1.80 | 77.92% | 113.4M | $3.0M | $1.58$80.85 |
| QCLS | TNF Pharmaceuticals, Inc. | $5.67 | $1.60 | 39.31% | 25.4M | $17M | $2.50$137.99 |
| EQPT | EquipmentShare.com | $32.56 | $8.06 | 32.90% | 17.4M | - | $28.00$33.00 |
| CHRS | Coherus Oncology | $2.06 | $0.47 | 29.56% | 21.5M | $192M | $0.71$2.17 |
| ANL | Adlai Nortye | $2.63 | $0.59 | 28.92% | 167.9K | $64M | $0.88$2.75 |
| KUST | Kustom Entertainment | $2.62 | $0.58 | 28.43% | 113.9M | $1.6M | $1.81$2,280.00 |
| LIF | Life360 | $68.10 | $13.29 | 24.25% | 3.6M | $4.3B | $29.62$112.54 |
| ADAG | Adagene | $2.49 | $0.46 | 22.66% | 2M | $96M | $1.30$3.16 |
Related Articles
Featured Article
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Alex Carchidi|Jun 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Coherus BioSciences Keeps Proving Wall Street Wrong
Maxx Chatsko|Aug 11, 2020
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
2 Top Small-Cap Stocks to Buy Right Now
Maxx Chatsko|Jun 12, 2020
Volatile stock market or not, these two drug developers are well positioned for long-term success.
Is Coherus BioSciences a Buy?
Maxx Chatsko|May 26, 2020
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys
Maxx Chatsko|Apr 17, 2020
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
2 Top Small-Cap Stocks to Buy in December
Maxx Chatsko|Dec 10, 2019
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
Maxx Chatsko|Nov 19, 2019
The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
Dan Caplinger|Jul 8, 2019
Bad news on multiple fronts hit stocks.
Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today
Dan Caplinger|Apr 8, 2019
Guess which of these stocks could see big changes ahead.
Why II-VI, Coherus Biosciences, and El Pollo Loco Holdings Jumped Today
Dan Caplinger|Mar 9, 2018
On a day the indexes advanced, these stocks saw outsize gains. Here's why.
